

AMENDMENTS TO THE CLAIMS

Claims 1-13 (Cancelled)

14. (Currently Amended) A method for the treatment ~~or prophylaxis~~ of a disease or condition selected from adult respiratory distress syndrome (ARDS), cystic fibrosis, chronic obstructive pulmonary disease (COPD), and asthma, which method comprises administering to a person suffering from or susceptible to such a disease or condition, a therapeutically effective amount of a compound of formula (I), ~~as defined in any one of Claims 15-17, or a pharmaceutically acceptable salt thereof.~~
15. (Previously Presented) A compound which is 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{{5-(methylsulfonyl)pyridin-2-yl)methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide, or a pharmaceutically acceptable salt thereof.
16. (Previously Presented) A compound which is 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{{5-(methylsulfonyl)pyridin-2-yl)methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide.
17. (Previously Presented) A compound which is a pharmaceutically acceptable salt of 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{{5-(methylsulfonyl)pyridin-2-yl)methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide
18. (Previously Presented) A pharmaceutical formulation comprising a compound, as defined in any one of Claims 15 to 17 in admixture with a pharmaceutically acceptable diluent or carrier.